Sprouts Farmers Market closes $600 million revolving credit facility
AUSTIN, Texas—Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), has recently sold shares of the company, according to a filing with the Securities and Exchange Commission. The transactions, carried out on March 17, involved the sale of 1,026 shares of common stock, amounting to a total value of $149,835. The sale comes as Natera, now valued at $20.4 billion, has seen its stock surge 62.4% over the past year, with InvestingPro data showing robust revenue growth of 56.8% in the last twelve months.
The shares were sold at prices ranging from $146.03 to $149.74 per share. Following these transactions, Moshkevich holds 144,782 shares of Natera. The sales were conducted to address tax withholding obligations related to the vesting of Restricted Stock Units (RSUs), as indicated by a footnote in the filing. According to InvestingPro analysis, Natera maintains a strong financial position with a current ratio of 4.0, indicating robust liquidity. Subscribers can access 10+ additional ProTips and comprehensive financial metrics in the Pro Research Report.
This move is part of a pre-arranged trading plan intended to comply with Rule 10b5-1(c) under the Securities Exchange Act, which allows major shareholders and insiders to sell a predetermined number of shares at a predetermined time. The stock has shown significant volatility, with InvestingPro data indicating the company maintains a GOOD overall financial health score despite current market fluctuations.
In other recent news, Natera has reported its fourth-quarter 2024 earnings, surpassing expectations with a revenue of $476 million, a 53% increase year-over-year, and a loss per share of -$0.41, better than the forecasted -$0.49. The company also reported a significant improvement in gross margins, reaching 63%, up from 51% the previous year, and generated $46 million in cash flow during the quarter. Canaccord Genuity responded to these results by maintaining a Buy rating on Natera and raising its price target to $195 from $180, citing strong performance and future revenue growth expectations. Similarly, TD Cowen reaffirmed its Buy rating with a $195 price target, noting Natera’s promising sales projections for 2025, which exceed consensus estimates by about 5%.
Additionally, Natera has launched the HEROES clinical trial in France, aiming to explore the potential for reducing therapy in metastatic HER2+ breast cancer patients, with the trial focusing on 1-year progression-free survival. The trial is sponsored by Unicancer and funded by the French Ministry of Health. Analysts from both Canaccord Genuity and TD Cowen expressed optimism about Natera’s future, emphasizing the company’s robust growth levers, including the anticipated rise in Signatera’s price and volume, and the expansion of profit margins and cash flow. These developments suggest a positive trajectory for Natera, supported by strategic operational expenditures and strong market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.